Inflammation is associated with incident hypertension in patients with axial spondyloarthritis: A longitudinal cohort study

被引:4
|
作者
Shi, Lin-Hong [1 ,2 ]
Lam, Steven H. H. [1 ]
So, Ho [1 ]
Chan, Crystal Y. Y. [3 ]
Li, Tena K. K. [1 ]
Szeto, Cheuk-Chun [1 ,2 ]
Tam, Lai-Shan [1 ,4 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci LiHS, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
关键词
Axial spondyloarthritis; incident hypertension; cardiovascular disease; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANKYLOSING-SPONDYLITIS; RETROSPECTIVE COHORT; BLOOD-PRESSURE; ATHEROSCLEROSIS; DISEASE; RISK;
D O I
10.1080/10641963.2023.2205056
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
KEY MESSAGES What is already known about this subject? center dot Patients with axial spondyloarthritis (axSpA) have a higher risk of cardiovascular (CV) disease compared with the general population. Hypertension (HT) is one of the most important modifiable risk factors. Whether increased inflammatory pathways or the use of anti-inflammatory therapies contribute toward the increased prevalence of HT in axSpA remained controversial. What does this study add? center dot First, higher inflammatory burden as reflected by a longer baseline disease duration, delay in diagnosis and higher ESR levels were predictors of incident HT (IHT) after adjusting for traditional CV risk factors in axSpA. Second, IHTrisk was significantly increased in pati\ents with disease duration >5 years. How might this impact on clinical practice or future developments? center dot Early diagnosis and adequate control of systematic inflammation may be important to prevent the development of HT. Routine screening for hypertension in axSpA patients should be considered, especially in patients with longer disease duration. Objectives To elucidate the risk factors for the development of incident hypertension (IHT) in patients with axial spondyloarthritis (axSpA). Methods We conducted a retrospective cohort study in axSpA patients who were recruited from 2001 to 2019 from a university clinic in Hong Kong. Patients with HT and/or anti-hypertensive drug use at baseline were excluded. They were followed until the end of 2020. The outcome was IHT, defined by a diagnosis and a prescription for an antihypertensive drug. Baseline and time-varying Cox regression analyses adjusting for age, sex, and body mass index (BMI), were used to assess the relationship between drug use, inflammatory burden, and IHT. Results Four hundred and thirteen patients [age: 34(25-43) years, male: 319 (77.2%)] were recruited. After a median follow-up of 12 (6-17) years, 58 patients (14%) developed IHT (IHT+group). Among all the baseline variables, disease duration and delay in diagnosis were the independent predictors for IHT based on the Cox regression model. In the multivariate Cox regression analysis, baseline disease duration, delay in diagnosis and time-varying ESR levels were independent predictors associated with an increased risk of IHT. IHT risk was significantly increased in patients with disease duration >5 years. The use of anti-inflammatory drugs was not associated with the development of IHT. Conclusion Higher inflammatory burden as reflected by a longer disease duration, delay diagnosis and higher ESR levels, were predictors associated with IHT after adjusting for traditional CV risk factors. These data support routine screening for hypertension in axSpA patients, especially those with longer disease duration.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The Risk of Demyelinating Diseases in Spondyloarthritis: A Longitudinal Cohort Study
    Remalante-Rayco, Patricia
    Daghistani, Yassir
    Espiritu, Adrian
    Jha, Mayank
    Chim, Tina
    Keshavarzi, Sareh
    Atenafu, Eshetu
    Oh, Jiwon
    Gladman, Dafna
    Inman, Robert
    Haroon, Nigil
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 65 - 66
  • [42] Presence and associated factors of fatigue in patients with axial spondyloarthritis: results from the European Map of Axial Spondyloarthritis
    Garrido-Cumbrera, M.
    Navarro-Compan, V.
    Christen, L.
    Bundy, C.
    Mahapatra, R.
    Makri, S.
    Delgado-Dominguez, C. J.
    Correa-Fernandez, J.
    Sanz-Gomez, S.
    Poddubnyy, D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 : 9 - 10
  • [43] FACTORS ASSOCIATED WITH FRAILTY STATUS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
    Ozturk, O.
    Feyzioglu, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1108 - 1109
  • [44] EFFECTIVENESS OF TNFI AFTER A FIRST SWITCH IS LOWER IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: A LONGITUDINAL ANALYSIS OF THE DESIR COHORT
    Pons, Marion
    Chevret, Sylvie
    Briot, Karine
    D'agostino, Maria-Antonietta
    Roux, Christian
    Dougados, Maxime
    Molto, Anna
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 72 - 72
  • [45] Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study
    Johnson, Tate
    Yang, Yangyuna
    Roul, Punyasha
    Baker, Joshua
    Sauer, Brian
    Cannon, Grant
    Kunkel, Gary
    Binstadt, Bryce
    Joseph, Amy
    Wysham, K.
    Lenert, Aleksander
    Kerr, Gail
    Reimold, Andreas
    Duryee, Michael
    Thiele, Geoffrey
    Mikuls, Ted R.
    England, Bryant
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2504 - 2506
  • [46] Muscle relaxant use and the associated risk of incident frailty in patients with diabetic kidney disease: a longitudinal cohort study
    Lee, Szu-Ying
    Wang, Jui
    Tsai, Hung-Bin
    Chao, Chia-Ter
    Chien, Kuo-Liong
    Huang, Jenq-Wen
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2021, 12
  • [47] COMPLEMENT IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS (AXSPA). INVESTIGATIONS IN A CROSS-SECTIONAL COHORT (OPTIREF) OF PATIENTS SUSPECTED OF AXIAL SPONDYLOARTHRITIS
    Mistegaard, C. E.
    Troldborg, A.
    Loft, A. G.
    Thiel, S.
    Spiller, L.
    Rodriguez, V. Rios
    Muche, B.
    Rademacher, J.
    Weber, A. K.
    Lueders, S.
    Sieper, J.
    Poddubnyy, D.
    Proft, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1225 - 1226
  • [48] EARLY FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT WITH BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS - RESULTS FROM A SINGLE CENTRE RETROSPECTIVE COHORT STUDY
    Costa, E.
    Lages, L.
    Almeida, D. Esperanca
    Correia, A. M. Gomes
    Cerqueira, M.
    Silva, J.
    Ribeiro, A. R.
    Costa, J. Redondo
    Neves, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1003 - 1004
  • [49] Early factors associated with the initiation of treatment with biologics in patients with Axial Spondyloarthritis - results from a single centre retrospective cohort study
    Lages, L.
    Costa, E.
    Almeida, D. E.
    Correia, M.
    Cerqueira, M.
    Leite-Silva, J.
    Costa, J. R.
    Ribeiro, A. R.
    Sousa-Neves, J.
    ACTA REUMATOLOGICA PORTUGUESA, 2021, 46 (03): : 230 - 238
  • [50] Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort
    Bedaiwi, Mohamed
    Sari, Ismail
    Thavaneswaran, Arane
    Ayearst, Renise
    Haroon, Nigil
    Inman, Robert D.
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (12) : 2354 - 2360